Therapeutic drug monitoring of valproic acid through

plasma concentration by Jakjimoska, Verica & Gjorgjeska, Biljana
 
 
Macedonian Pharmaceutical Bulletin, 66 (Suppl 1) 5 - 6 (2020) 
Online ISSN 1857 - 8969  















General City Hospital “8th September”, Central Biochemical Laboratory, Pariska bb,                                     
1000 Skopje, N. Macedonia  
2
Faculty of Medical Science, University “Goce Delcev” Stip, Krste Misirkov 10A, 2000 Stip, N. Macedonia 
Introduction 
 
Therapeutic drug monitoring is the measurement 
of specific drug and/or their breakdown products 
(metabolites) at timed intervals to maintain a 
relatively constant concentration of the medication 
in the blood. Some of the monitored drugs tend to 
have a narrow “therapeutic index”, which is a ratio 
between the toxic and therapeutic (effective) dose of 
medication. 
Burtn et al. (2006) have shown that valproic acid 
is an 8-carbon 2-chain fatty acid that is metabolized 
by the liver and processed at a variable rate based on 
the patient’s liver function and age, in addition to 
patient’s other routine medications with which 
valproic acid may interact. At therapeutic 
concentrations, valproic acid mediates prolonged 
recovery of voltage-activated Na
+
 channels, thereby 
inhibiting repetitive firing induced by depolarization 
of cortical and spinal cord neurons.  
Unborn babies exposed to valproate are at very 
high risk of neurodevelopment disability and other 
birth defects and the need for effective contraception 
planning must also be emphasized, along with the 
requirement for specialist oversight to safely change 
their medication if planning a pregnancy according 
toMarshall and Bangert (2008). 
The determination of an antiepileptic drug 
concentration is recommended as a baseline 
measurement after starting drug therapy, according 
to NICE Clinical Guideline 137 (2020), after a 
change in the drug dose regimen, after addition of a 
second drug that may interact with the antiepileptic 
drug, and after a change in the patient’s liver, 
cardiac, or gastrointestinal function.According to 
NICE Clinical Guideline 38 (2020), measurement of 
an antiepileptic drug concentration is usually 
performed after 4 to 5 elimination half-lives of drug 
administration, that is, once a steady state 
concentration has been achieved.  
 
Materials and methods 
 
This is a retrospective study on 40 patients over 
the period from January the 9
th 
to March the 11
th 
2020. All serum samples were selected from 
specimens submitted to the laboratory for routine 
antiepileptic drug testing for valproic acid. The 
analyses were performed using an automated 
analyzer Immulite 2000, competitive immunoassay 
methods for the quantitative measurement of 
valproic acid. The Immulite 2000 is an automated 
random access analyzer that uses 
chemiluminescence technology. 
The therapeutic range for valproic acid is 50-100 
mcg/mL, sub-normal level is < 50mcg/mL, and the 
toxic level is > 100 mcg/mL. 
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Result and discussion 
 
In this study were analyzed 40 patients coming 
from the department of neurology and psychiatry, 
patients with epilepsy or with bipolar mood 
disorders and other neuralgia. Males represented 
37.5% of the total number of patients, and females 
62.5%, which is 25% more than males, showing that 
females are more vulnerable. Standard deviation for 
patient’s age within this population with 95% 
confidence interval was 45.9±5.4 years. Female 
only, has shown lower age standard deviation with 
95% confidence interval of 32.5±2.5 years. 
Approximately 42.5% of the population were with 
normal serum level of valproic acid (50-100 
mcg/mL), and 57.5% were with sub-normal serum 
level of valproic acid (< 50mcg/mL), and none with 
toxic level of valproic acid (> 100mcg/mL) in serum 
samples. Within 95% confidence interval, serum 
levels were measured to be 46.4±7.5 (±16%) 
mcg/mL. Mean of inter-individual variability in 
valproic acid serum concentrations were 38.9% CV 
for dose of 400mg/day, 45.8% CV for dose of 600 
mg/day, and 14.25% CV for dose of 800 mg/day. 
As demonstrated (Warner et al., 1998), many of 
the drugs that require therapeutic monitoring are 
taken for a lifetime. They must be maintained at 
steady concentrations year after year while the 
person ages and goes through life events that may 
alter that individual's therapeutic level, including 
pregnancies, temporary illnesses, infections, 
emotional and physical stresses, accidents, and 
surgeries. 
Tests that measure drug concentration in serum 
are used to monitor blood levels of drugs that have a 
narrow range in which the drug is effective, but not 
toxic. It was shown that no toxicity was found and 
therapeutic response was satisfying within 42.5% of 
the patients. There is significant number of patients 
(57.5%) with sub-normal serum level of valproic 
acid, partially because this low level has satisfactory 
therapeutic response, but there is still chance for 
non-compliance. In addition, Shaikh (2018) 
demonstrated that some drugs require monitoring 
because the dosage of drug given does not correlate 
well with the concentration of drug that may reach 
the blood. Sometimes, the way that a drug is 
absorbed and metabolized can vary from person to 
person, or the physical or health status of a person 
can affect the drug level in the blood. Through years 
of testing, the optimum therapeutic ranges for drugs 
have been determined. In these ranges, most people 
will be effectively treated without excessive side 




Patients treated with valproic acid are most 
likely woman at the age of 30-35 years, still in 
reproductive period and have childbearing potential. 
This fact requires protection for girls and young 
women, and using valproic acid only when other 
medications have not been tolerated or have been 
found to be ineffective. It is vital where valproate is 
prescribed to girls and women of childbearing 
potential that they are made aware of the risks of 
taking the medication in pregnancy. Sub-normal 
level of valproic acid in serum is partially because 
this low level has satisfactory therapeutic response 
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